Facebook
Facebook
This 2009 NCDEU Poster Session was published in October 2009 and is eligible for AMA PRA Category 1 Credit™ through April 30, 2010. The latest review of this material was September 2009.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
After completing this educational activity, you should be able to:
This special 2009 NCDEU Annual Meeting Poster Session was developed for CME credit designation on the basis of our assessment of the needs of Web site visitors, with the purpose of providing visitors with a curriculum of posters on a variety of topics.
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The CME Institute of Physicians Postgraduate Press, Inc., designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The presenters for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal financial relationships between themselves and their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Financial disclosures from the presenters are as follows:
Dr Blier is a consultant for Biovail, Eli Lilly, Janssen, Lundbeck, Schering-Plough, Sepracor, Wyeth, Sanofi-Aventis, AstraZeneca, Pfizer, Novartis, Takeda, Bristol-Myers Squibb, and Servier; has received grant funding from Cyberonics, Labopharm, Janssen, Lundbeck, Mitsubishi Pharma, Schering-Plough, Sepracor, Wyeth, Bristol-Myers Squibb, and Servier; is a member of the speakers bureau for Janssen, Lundbeck, and Wyeth; and is a contract employee of Janssen and Steelbeach Productions.
Dr Kane is a consultant for AstraZeneca, Bristol-Myers Squibb, Otsuka, Johnson & Johnson, Janssen, Cephalon, Eli Lilly, Wyeth, Proteus, and Lundbeck and has received honoraria from Janssen, Eli Lilly, Otsuka, and Bristol-Myers Squibb.
Dr Keefe. From January 2007 to September 1, 2008, Dr Keefe was a consultant for Acadia, Bristol-Myers Squibb, Cortex, Cephalon, Orexigen, and Schering-Plough, and was a member of the advisory board for and received an unrestricted educational grant from Organon. Currently (during the past 12 months), Dr Keefe is a consultant for Abbott, BiolineRx, Dainippon Sumimoto, Eli Lilly, Johnson & Johnson, Lundbeck, Memory Pharmaceuticals, Merck, NeuroSearch, Orion, Otsuka, Pfizer, Roche, Sanofi-Aventis, Wyeth, and Xenoport; has received honoraria from AstraZeneca and Bristol-Myers Squibb; has received an unrestricted educational grant from AstraZeneca; has received research funding from Eli Lilly and Pfizer; is a speaker or member of the advisory board for Eli Lilly and Wyeth; and has received royalties for the Brief Assessment of Cognition (BACS) and the MATRICS Battery (BACS Symbol Coding).
Dr Patkar has received grant/research support from AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer and Specialty, Organon, Orphan Medical, Titan, and Pfizer; is a consultant for Bristol-Myers Squibb, Reckitt Benckiser, and Forest; is a member of the speakers/advisory board for and has received honoraria from Bristol-Myers Squibb, Pfizer, Reckitt Benckiser, and Cephalon; and conducts clinical trials for AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, Jazz, Lundbeck, McNeil Consumer and Specialty, Organon, Merck, Titan, and Pfizer.
Dr Tiller is an employee and stock shareholder of Cephalon Inc. Her spouse is an employee and stock shareholder of GlaxoSmithKline.
Dr Yang is an employee and stock shareholder of Cephalon Inc.
Dr Youakim is an employee and stock shareholder of Cephalon Inc.
Dr Zernig is a consultant for Lundbeck and Wyeth and is a member of the advisory board for Lundbeck.
Drs Chenu, D’Souza, Teter, and Weiss, and Ms Batten, Hebert, Ladstaetter, and Lower, and Mr Falone have no personal financial relationships to disclose relative to this presentation.
In this 2009 NCDEU Poster Session, participants may be presenting investigational information about pharmaceutical agents that is outside US Food and Administration–labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
This 2009 NCDEU Poster Session has been reviewed for accuracy and fair balance by a selection committee of the American Society of Clinical Psychopharmacology (ASCP), and a member of the External CME Advisory Board has reviewed this poster session to determine whether the material is evidence-based and objective.
This 2009 NCDEU Poster Session is derived from the 49th Annual NCDEU Meeting, which was held June 29–July 2, 2009, in Hollywood, Florida, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., the National Institute of Mental Health (NIMH), and the ASCP. The opinions expressed herein are those of the presenters and do not necessarily reflect the opinions of the CME provider and publisher, the NIMH, or the ASCP.
Psychiatrist.com Home
Keyword Search